AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 285 participants.
Also called NCT07697391
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 285 participants
- Registry
-
NCT07697391
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07697391. Randomized; no masking; primary purpose treatment. Start 2026-07-16 (actual); primary completion 2027-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- Acronym
- AI-LIFE-T2D-OB
- Condition
- Obesity
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Behavioral)
- AI-Assisted Intensive Lifestyle Intervention
- Intervention (Drug)
- Tirzepatide
- Intervention (Behavioral)
- Standard Lifestyle Management
- Lead sponsor
- The First Affiliated Hospital of Anhui Medical University
- Collaborator
- Zhejiang Nutriease Health Technology Co. Ltd.
Record details
- Record id
cardio:ct-nct07697391- Content hash
28690fdd0fe34b6fff60a9ae14e0883e018ab23cb85a27ef049460608d26144f